David Collier

David is the Chief Executive Officer of X-37. He has had a long career in creating and financing new biotechnology companies, primarily focusing on the discovery and development of new pharmaceutical candidates.

As an investor, David has worked as a Managing Director at the San Francisco-based venture capital firm Presidio Partners (www.presidiopartners.com) since 2001. While at Presidio, David made many investments in promising early-stage biotechnology companies. Notable successes include Biomimetic Therapeutics (IPO, then acquired by Wright Medical), Centrexion Therapeutics, Altus Pharmaceuticals (IPO), and Auspex Pharmaceuticals (IPO, then acquired by Teva).

In addition to co-founding X-37, David co-founded Velocity Pharmaceutical Development (www.vpd.net) in 2011 and has led the company as its CEO since then. David played a major role in in-licensing serlopitant from Merck & Co. to create Tigercat Pharma (now Menlo Therapeutics, NASDAQ: MNLO), in the sale of Spitfire Pharma to Altimmune, Inc. (NASDAQ: ALT), and in negotiating the strategic partnership between Corsair Pharma and United Therapeutics.

David currently serves as a member of the board of directors of Exela Pharma Sciences (www.exelapharma.com).

David holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Physics from Wesleyan University.